Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sarepta Therapeutics Inc Says FDA Raises Doubt About Drug Trial-Reuters


Tuesday, 12 Nov 2013 07:00am EST 

Reuters reported that Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had raised concerns about the trial for the Company's experimental muscle disorder drug and considered the marketing application for the treatment to be premature. Sarepta shares fell in premarket trade on Tuesday. 

Company Quote

25.19
0.24 +0.96%
3:12pm EDT